Pediatr. pro Praxi, 2001; 3: 116-119

Blokátory kalciových kanálů v léčbě hypertenze u dětí

MUDr. Lenka Kopečná Ph.D
I. dětská interní a onkologická klinika LF MU a FN, Brno

Keywords: hypertension, blocators of calcium canals, childhood

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopečná L. Blokátory kalciových kanálů v léčbě hypertenze u dětí. Pediatr. praxi. 2001;2(3):116-119.

Včasná detekce a racionální léčba hypertenze (HT) je nezbytná. I široké pediatrické veřejnosti dnes není neznámé jak správně krevní tlak měřit, získané hodnoty interpretovat, včetně racionálního a objektivního vyšetření krevního tlaku pomocí metody ABPM. V dětském věku je převažující HT sekundární, zejména pak podmíněná poškozením ledvinného parenchymu a/nebo v důsledku abnormit cévního zásobení ledvin. Současné spektrum antihypertenziv vhodných pro dětský věk je dostatečně široké, preferovány jsou především léky ze skupiny inhibitorů angiotenzin konvertujícího enzymu nebo blokátory kalciových kanálů (BKK). Doposud není v pediatrické literatuře široce referováno o zkušenostech s podáváním BKK. Převažují přitom reference hodnotící vliv těchto léků na akutní HT, problematika déledobého podávání BKK u dětské populace je zastoupena ojediněle. Práce podává současný literární přehled použití BKK u dětí s HT.

Blocators of calcium canals in the treatment of hypertension in children

An early detection and rationally treatment of hypertension is a necessity. For pediatrists community is well known how to meassure the blood pressure in the right way, how to interpret the values include of outfinding by ABPM-method. At the childhood the HT secundary is predominantly, meanly if it is caused by arrosion of renal parenchyma and/or in consequence of abnormities of renal vascularity. The contemporary spectrum of antihypertensive medicaments suitable for childhood is spread enough, prefered are in advance inhibitors of angiotensin converted to enzyms or calcium canals blocators (CCB). Till now it is no refered in the pediatric literature about calcium canals blokators. More articles refered how this medicaments involves acute hypertension but a few of about longterm intaking of CCB. This article showes a contemporary literary review of calcium canals blocators using in children with hypertension.

Download citation

References

  1. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15: 302-316. Go to original source... Go to PubMed...
  2. Perez-Reyes E, Schneider T. Molecular biology of calcium channels. Kidney Int 1995; 48: 1111-1124. Go to original source... Go to PubMed...
  3. Nargeot J, Lory P, Richard S. Molecular basis of the diversity of calcium channels in cardiovascular tissues. Eur Heart 1997; 18: A15-A26. Go to original source... Go to PubMed...
  4. Triggle DJ. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels. Am J Hypertens 1998; 11: 80S-87S. Go to original source... Go to PubMed...
  5. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. Drugs 1998; 55: 509-517. Go to original source... Go to PubMed...
  6. Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young 1998; 8: 310-319. Go to original source... Go to PubMed...
  7. Porter CJ, Garson A, Gillette PC. Verapamil: an effective calcium channel blocking agent for pediatric patients. Pediatrics 1983; 71: 748-755. Go to original source... Go to PubMed...
  8. Houde C, Bohn DJ, Freedom RM, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsivenes to vasodilators. Br Heart J 1993; 70: 461-468. Go to original source... Go to PubMed...
  9. Islam S, Masiakos P, Schnitzer JJ et al. Diltiazem reduces pulmonary arterial pressures in recurrent pulmonary hypertension associated with pulmonary hypoplasia. J Pediatr Surg 1999; 34: 712-714. Go to original source... Go to PubMed...
  10. Bertorini TE, Palmieri GM, Griffin JW et al. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy. Neurology 1988; 38: 609-613. Go to original source... Go to PubMed...
  11. Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996; 23: 2152-2155. Go to PubMed...
  12. al Edreesi M, Caille G, Dupuis C et al. Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine. Liver Transpl Surg 1995; 1: 383-388. Go to original source... Go to PubMed...
  13. Dilmen U, Caglar K, Senses DA, Kinik E. Nifedipine in hypertensive emergencies in children. Am J Dis Child 1983; 137: 1162-1165. Go to original source... Go to PubMed...
  14. Roth B, Herkenrath P, Krebber J, Abu-Chaaban M. Nifedipine in hypertensive crises of infants and children. Clin Exp Hypertens 1986; 8: 871-877. Go to original source... Go to PubMed...
  15. Siegler RL, Brewer ED. Effect of sublingual or oral nifedipine in the treatment of hypertension. J Pediatr 1988; 112: 811-813. Go to original source... Go to PubMed...
  16. Doležel Z. Akutní/těžká hypertenze u dětí - současný léčebný postup. Pediatrie pro praxi 2000; 1: 109-110.
  17. Doležel Z.: Hypertenze v dětském věku. Causa subita 1999; 12: 27-29.
  18. Evans JHC, Shaw NJ, Brocklebank JT. Sublingual nifedipine in acute severe hypertension. Arch Dis Child 1988; 63: 975-977. Go to original source... Go to PubMed...
  19. Johnson CE, Jacobson PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Am Pharmacother 1997; 31: 704-707. Go to original source... Go to PubMed...
  20. Flynn JT, Kershaw DB, Sedman AB et al. Efficacy of isradipine as an antihypertensive agent in children (abstract). Pediatr Res 1998; 43: 307A. Go to original source...
  21. Moncica I, Oh PI, ul Qamar I et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child 1995; 73: 154-156. Go to original source... Go to PubMed...
  22. Blowey DL, Moncica I, Scolnik D et al. The pharmacokinetics of extended release felodipine in children. Eur j Clin Pharmacol 1996; 50: 147-148. Go to original source... Go to PubMed...
  23. Gitomer JJ, Grimm EM, Bonilla-Felix MA et al. The safety and efficacy of the calcium channel blocker (CCB) amlodipine in the treatment of secondary hypertension in children (abstract). Pediatr Res 1998; 43: 308A. Go to original source...
  24. Tallian KB, Nahata MC, Turman MA et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13: 304-310. Go to original source... Go to PubMed...
  25. Flynn JT, Smoyer WE, Bunchman TE. Amlodipine effectively controls blood pressure in children with hypertension. Am J Hypertens 2000 (in press).
  26. Treluyer JM, Hubert P, Jouvet P et al. Intravenous nicardipine in hypertensive children. Eur J Pediatr 1993; 152: 712-714. Go to original source... Go to PubMed...
  27. Michael J, Groshong T, Tobias JD. Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 1998; 12: 40-42. Go to original source... Go to PubMed...
  28. Flynn JT, Mottes TA, Kershaw DB et al. Safety and efficacy of nicardipine for hypertensive emergencies in children (abstract). Am J Hypertens 1999; 12: 124A. Go to original source...
  29. Gouyon JB, Ganeste B, Semama DS et al. Intravenous nicardipine in hypertensive preterm infants. Eur J Pediatr 1993; 152: 712-714. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.